{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,10,7]],"date-time":"2023-10-07T02:39:23Z","timestamp":1696646363638},"reference-count":68,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2012,7,1]],"date-time":"2012-07-01T00:00:00Z","timestamp":1341100800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Geriatric Oncology"],"published-print":{"date-parts":[[2012,7]]},"DOI":"10.1016\/j.jgo.2012.02.001","type":"journal-article","created":{"date-parts":[[2012,2,28]],"date-time":"2012-02-28T06:24:57Z","timestamp":1330410297000},"page":"279-290","source":"Crossref","is-referenced-by-count":3,"title":["New treatment approaches for older adults with multiple myeloma"],"prefix":"10.1016","volume":"3","author":[{"given":"Tanya M.","family":"Wildes","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ravi","family":"Vij","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen H.","family":"Petersdorf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruno C.","family":"Medeiros","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arti","family":"Hurria","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"17","key":"10.1016\/j.jgo.2012.02.001_bb0005","doi-asserted-by":"crossref","first-page":"2758","DOI":"10.1200\/JCO.2008.20.8983","article-title":"Future of cancer incidence in the United States: burdens upon an aging, changing nation","volume":"27","author":"Smith","year":"2009","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.jgo.2012.02.001_bb0010","doi-asserted-by":"crossref","first-page":"21","DOI":"10.4065\/78.1.21","article-title":"Review of 1027 patients with newly diagnosed multiple myeloma","volume":"78","author":"Kyle","year":"2003","journal-title":"Mayo Clin Proc"},{"issue":"2","key":"10.1016\/j.jgo.2012.02.001_bb0015","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1056\/NEJM199607113350204","article-title":"A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome","volume":"335","author":"Attal","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jgo.2012.02.001_bb0020","series-title":"13th International Myeloma Workshop; 2011 May 6, 2011","article-title":"Declining myeloma mortality rates in the United States following introduction of novel therapies","author":"Libby","year":"2011"},{"issue":"5","key":"10.1016\/j.jgo.2012.02.001_bb0030","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1182\/blood-2007-08-104984","article-title":"Recent major improvement in long-term survival of younger patients with multiple myeloma","volume":"111","author":"Brenner","year":"2008","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.jgo.2012.02.001_bb0035","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1634\/theoncologist.2011-0229","article-title":"Improvement in survival of older adults with multiple myeloma: results of an updated period analysis of SEER data","volume":"16","author":"Pulte","year":"2011","journal-title":"Oncologist"},{"issue":"9","key":"10.1016\/j.jgo.2012.02.001_bb0040","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1001\/jama.1969.03160090040009","article-title":"Treatment for multiple myeloma. Combination chemotherapy with different melphalan dose regimens","volume":"208","author":"Alexanian","year":"1969","journal-title":"JAMA"},{"issue":"15","key":"10.1016\/j.jgo.2012.02.001_bb0045","doi-asserted-by":"crossref","first-page":"3435","DOI":"10.1182\/blood-2008-07-169565","article-title":"Thalidomide\u2013dexamethasone compared with melphalan\u2013prednisolone in elderly patients with multiple myeloma","volume":"113","author":"Ludwig","year":"2009","journal-title":"Blood"},{"issue":"9513","key":"10.1016\/j.jgo.2012.02.001_bb0050","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/S0140-6736(06)68338-4","article-title":"Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial","volume":"367","author":"Palumbo","year":"2006","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.jgo.2012.02.001_bb0055","doi-asserted-by":"crossref","first-page":"3107","DOI":"10.1182\/blood-2008-04-149427","article-title":"Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial","volume":"112","author":"Palumbo","year":"2008","journal-title":"Blood"},{"issue":"9594","key":"10.1016\/j.jgo.2012.02.001_bb0060","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/S0140-6736(07)61537-2","article-title":"Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial","volume":"370","author":"Facon","year":"2007","journal-title":"Lancet"},{"issue":"22","key":"10.1016\/j.jgo.2012.02.001_bb0065","doi-asserted-by":"crossref","first-page":"3664","DOI":"10.1200\/JCO.2008.21.0948","article-title":"Efficacy of melphalan and prednisone plus thalidomide in patients older than 75years with newly diagnosed multiple myeloma: IFM 01\/01 trial","volume":"27","author":"Hulin","year":"2009","journal-title":"J Clin Oncol"},{"issue":"19","key":"10.1016\/j.jgo.2012.02.001_bb0070","doi-asserted-by":"crossref","first-page":"3160","DOI":"10.1200\/JCO.2009.26.1610","article-title":"Phase III study of the value of thalidomide added to melphalan plus prednisone in elderly patients with newly diagnosed multiple myeloma: the HOVON 49 Study","volume":"28","author":"Wijermans","year":"2010","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.jgo.2012.02.001_bb0075","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1182\/blood-2009-08-237974","article-title":"Melphalan and prednisone plus thalidomide or placebo in elderly patients with multiple myeloma","volume":"116","author":"Waage","year":"2010","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.jgo.2012.02.001_bb0080","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/j.1600-0609.2010.01524.x","article-title":"Addition of thalidomide to oral melphalan\/prednisone in patients with multiple myeloma not eligible for transplantation: results of a randomized trial from the Turkish Myeloma Study Group","volume":"86","author":"Beksac","year":"2010","journal-title":"Eur J Haematol"},{"issue":"10","key":"10.1016\/j.jgo.2012.02.001_bb0085","doi-asserted-by":"crossref","first-page":"1942","DOI":"10.3109\/10428194.2011.584006","article-title":"A randomized trial with melphalan and prednisone versus melphalan and prednisone plus thalidomide in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplant","volume":"52","author":"Sacchi","year":"2011","journal-title":"Leuk Lymphoma"},{"issue":"5","key":"10.1016\/j.jgo.2012.02.001_bb0090","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1182\/blood-2011-03-341669","article-title":"Thalidomide for previously untreated elderly patients with multiple myeloma: meta-analysis of 1685 individual patient data from 6 randomized clinical trials","volume":"118","author":"Fayers","year":"2011","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.jgo.2012.02.001_bb0095","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1038\/leu.2010.313","article-title":"Melphalan and prednisone versus melphalan, prednisone and thalidomide for elderly and\/or transplant ineligible patients with multiple myeloma: a meta-analysis","volume":"25","author":"Kapoor","year":"2011","journal-title":"Leukemia"},{"issue":"7","key":"10.1016\/j.jgo.2012.02.001_bb0100","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.1182\/blood-2006-04-019778","article-title":"Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1\/2 study","volume":"108","author":"Mateos","year":"2006","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.jgo.2012.02.001_bb0105","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1200\/JCO.2009.26.0638","article-title":"Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial","volume":"28","author":"Mateos","year":"2010","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.jgo.2012.02.001_bb0110","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1056\/NEJMoa0801479","article-title":"Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma","volume":"359","author":"San Miguel","year":"2008","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.jgo.2012.02.001_bb0115","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/S1470-2045(10)70187-X","volume":"11","author":"Mateos","year":"2010","journal-title":"Lancet Oncol"},{"issue":"21","key":"10.1016\/j.jgo.2012.02.001_bb0120","first-page":"619","article-title":"Phase 3b UPFRONT study: safety and efficacy of weekly bortezomib maintenance therapy after bortezomib-based induction regimens in elderly, newly diagnosed multiple myeloma patients","volume":"116","author":"Niesvizky","year":"2010","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"10.1016\/j.jgo.2012.02.001_bb0125","first-page":"3026","article-title":"Patient-reported quality of life in elderly, newly diagnosed multiple myeloma patients treated with bortezomib-based regimens: results from the phase 3b UPFRONT study","volume":"116","author":"Niesvizky","year":"2010","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"34","key":"10.1016\/j.jgo.2012.02.001_bb0130","doi-asserted-by":"crossref","first-page":"5101","DOI":"10.1200\/JCO.2010.29.8216","article-title":"Bortezomib\u2013melphalan\u2013prednisone\u2013thalidomide followed by maintenance with bortezomib\u2013thalidomide compared with bortezomib\u2013melphalan\u2013prednisone for initial treatment of multiple myeloma: a randomized controlled trial","volume":"28","author":"Palumbo","year":"2010","journal-title":"J Clin Oncol"},{"issue":"23","key":"10.1016\/j.jgo.2012.02.001_bb0135","doi-asserted-by":"crossref","first-page":"4745","DOI":"10.1182\/blood-2010-07-294983","article-title":"Efficacy and safety of once-weekly bortezomib in multiple myeloma patients","volume":"116","author":"Bringhen","year":"2010","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.jgo.2012.02.001_bb0140","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S1470-2045(09)70284-0","article-title":"Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial","volume":"11","author":"Rajkumar","year":"2010","journal-title":"Lancet Oncol"},{"issue":"28","key":"10.1016\/j.jgo.2012.02.001_bb0145","doi-asserted-by":"crossref","first-page":"4459","DOI":"10.1200\/JCO.2007.12.3463","article-title":"Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA\u2014Italian Multiple Myeloma Network","volume":"25","author":"Palumbo","year":"2007","journal-title":"J Clin Oncol"},{"issue":"21","key":"10.1016\/j.jgo.2012.02.001_bb0150","first-page":"622","article-title":"A phase 3 study evaluating the efficacy and safety of lenalidomide combined with melphalan and prednisone in patients >=65years with newly diagnosed multiple myeloma (NDMM): continuous use of lenalidomide vs fixed-duration regimens","volume":"116","author":"Palumbo","year":"2010","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"S1","key":"10.1016\/j.jgo.2012.02.001_bb0155","first-page":"234","article-title":"A phase III study to determine the efficacy and safety of lenalidomide combined with melphalan and prednisone in patients 65years with newly diagnosed multiple myeloma (NDMM)","volume":"95","author":"Palumbo","year":"2010","journal-title":"Haematologica"},{"issue":"21","key":"10.1016\/j.jgo.2012.02.001_bb0160","first-page":"475","volume":"118","author":"Palumbo","year":"2011","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"7","key":"10.1016\/j.jgo.2012.02.001_bb0165","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1182\/blood-2006-03-013086","article-title":"Thalidomide, dexamethasone, and pegylated liposomal doxorubicin (ThaDD) for patients older than 65years with newly diagnosed multiple myeloma","volume":"108","author":"Offidani","year":"2006","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.jgo.2012.02.001_bb0170","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1182\/blood-2011-02-338665","article-title":"Cyclophosphamide, thalidomide, and dexamethasone (CTD) as initial therapy for patients with multiple myeloma unsuitable for autologous transplantation","volume":"118","author":"Morgan","year":"2011","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.jgo.2012.02.001_bb0175","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1046\/j.1365-2141.2001.02976.x","article-title":"Autologous stem cell transplantation in elderly multiple myeloma patients over the age of 70years","volume":"114","author":"Badros","year":"2001","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.jgo.2012.02.001_bb0180","doi-asserted-by":"crossref","first-page":"118","DOI":"10.3109\/10428194.2011.606942","article-title":"Feasibility of autologous hematopoietic stem cell transplantation in patients aged \u226570years with multiple myeloma","volume":"53","author":"Bashir","year":"2012","journal-title":"Leuk Lymphoma"},{"issue":"8","key":"10.1016\/j.jgo.2012.02.001_bb0185","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1002\/ajh.21191","article-title":"Autologous stem cell transplantation in patients of 70 years and older with multiple myeloma: Results from a matched pair analysis","volume":"83","author":"Kumar","year":"2008","journal-title":"Am J Hematol"},{"issue":"10","key":"10.1016\/j.jgo.2012.02.001_bb0190","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1038\/sj.bmt.1705360","article-title":"High-dose melphalan (200mg\/m2) supported by autologous stem cell transplantation is safe and effective in elderly (>65years) myeloma patients: comparison with younger patients treated on the same protocol","volume":"37","author":"Jantunen","year":"2006","journal-title":"Bone Marrow Transplant"},{"issue":"12","key":"10.1016\/j.jgo.2012.02.001_bb0195","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1038\/sj.bmt.1704288","article-title":"Autologous stem cell transplantation in multiple myeloma patients <60 vs >\/=60years of age","volume":"32","author":"Reece","year":"2003","journal-title":"Bone Marrow Transplant"},{"issue":"5","key":"10.1016\/j.jgo.2012.02.001_bb0200","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1038\/sj.bmt.1702188","article-title":"The role of autologous transplantation in patients with multiple myeloma aged 65years and over","volume":"25","author":"Sirohi","year":"2000","journal-title":"Bone Marrow Transplant"},{"issue":"10","key":"10.1016\/j.jgo.2012.02.001_bb0205","doi-asserted-by":"crossref","first-page":"3052","DOI":"10.1182\/blood-2004-02-0408","article-title":"Intermediate-dose melphalan improves survival of myeloma patients aged 50 to 70: results of a randomized controlled trial","volume":"104","author":"Palumbo","year":"2004","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.jgo.2012.02.001_bb0210","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1200\/JCO.2009.22.7561","article-title":"Bortezomib as induction before autologous transplantation, followed by lenalidomide as consolidation-maintenance in untreated multiple myeloma patients","volume":"28","author":"Palumbo","year":"2010","journal-title":"J Clin Oncol"},{"issue":"21","key":"10.1016\/j.jgo.2012.02.001_bb0215","first-page":"620","article-title":"Bortezomib, melphalan, prednisone and thalidomide followed by maintenance with bortezomib and thalidomide (VMPT-VT) for initial treatment of elderly multiple myeloma patients: updated follow-up and impact of prognostic factors","volume":"116","author":"Palumbo","year":"2010","journal-title":"ASH Annual Meeting Abstracts."},{"issue":"21","key":"10.1016\/j.jgo.2012.02.001_bb0220","first-page":"477","article-title":"Maintenance therapy with bortezomib plus thalidomide (VT) or bortezomib plus prednisone (VP) in elderly myeloma patients included in the GEM2005MAS65 Spanish randomized trial","volume":"118","author":"Mateos","year":"2011","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"11","key":"10.1016\/j.jgo.2012.02.001_bb0225","doi-asserted-by":"crossref","first-page":"3025","DOI":"10.1182\/blood-2010-09-307645","article-title":"Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents: analysis of 1175 patients","volume":"117","author":"Gay","year":"2011","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.jgo.2012.02.001_bb0230","first-page":"3551","article-title":"Lenalidomide (L) in combination with dexamethasone (D) improves survival and time to progression in elderly patients (pts) with relapsed or refractory (rel\/ref) multiple myeloma (MM)","volume":"108","author":"Chanan-Khan","year":"2006","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"5","key":"10.1016\/j.jgo.2012.02.001_bb0235","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1111\/j.1365-2141.2007.06585.x","article-title":"Safety and efficacy of bortezomib in high-risk and elderly patients with relapsed multiple myeloma","volume":"137","author":"Richardson","year":"2007","journal-title":"Br J Haematol"},{"issue":"11","key":"10.1016\/j.jgo.2012.02.001_bb0240","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1056\/NEJMra1011442","article-title":"Multiple myeloma","volume":"364","author":"Palumbo","year":"2011","journal-title":"N Eng J Med"},{"issue":"17","key":"10.1016\/j.jgo.2012.02.001_bb0245","doi-asserted-by":"crossref","first-page":"4519","DOI":"10.1182\/blood-2011-06-358812","article-title":"Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN)","volume":"118","author":"Palumbo","year":"2011","journal-title":"Blood"},{"issue":"Suppl. 1","key":"10.1016\/j.jgo.2012.02.001_bb0250","doi-asserted-by":"crossref","first-page":"S45","DOI":"10.1002\/dmrr.856","article-title":"Neuropathy: mobility and quality of life","volume":"24","author":"van Schie","year":"2008","journal-title":"Diabetes Metab Res Rev"},{"issue":"11","key":"10.1016\/j.jgo.2012.02.001_bb0255","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1016\/S1470-2045(10)70068-1","article-title":"Treatment-related peripheral neuropathy in multiple myeloma: the challenge continues","volume":"11","author":"Delforge","year":"2010","journal-title":"Lancet Oncol"},{"issue":"11","key":"10.1016\/j.jgo.2012.02.001_bb0260","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.3109\/10428194.2011.598253","article-title":"Prevalence of peripheral neuropathy in multiple myeloma at initial diagnosis","volume":"52","author":"Malhotra","year":"2011","journal-title":"Leuk Lymphoma"},{"issue":"6","key":"10.1016\/j.jgo.2012.02.001_bb0265","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1212\/01.wnl.0000267271.18475.fe","article-title":"Neuropathy in multiple myeloma treated with thalidomide","volume":"69","author":"Plasmati","year":"2007","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.jgo.2012.02.001_bb0270","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1111\/j.1600-0609.2004.00382.x","article-title":"Neurological toxicity of long-term (>1yr) thalidomide therapy in patients with multiple myeloma","volume":"74","author":"Tosi","year":"2005","journal-title":"Eur J Haematol"},{"issue":"5","key":"10.1016\/j.jgo.2012.02.001_bb0275","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1111\/j.1365-2141.2005.05914.x","article-title":"A systematic review of phase-II trials of thalidomide monotherapy in patients with relapsed or refractory multiple myeloma","volume":"132","author":"Glasmacher","year":"2006","journal-title":"Br J Haematol"},{"issue":"21","key":"10.1016\/j.jgo.2012.02.001_bb0280","doi-asserted-by":"crossref","first-page":"3518","DOI":"10.1200\/JCO.2008.18.3087","article-title":"Single-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy","volume":"27","author":"Richardson","year":"2009","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.jgo.2012.02.001_bb0285","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1002\/cncr.22921","article-title":"Neurotoxicity of bortezomib therapy in multiple myeloma: a single-center experience and review of the literature","volume":"110","author":"Badros","year":"2007","journal-title":"Cancer"},{"issue":"19","key":"10.1016\/j.jgo.2012.02.001_bb0290","doi-asserted-by":"crossref","first-page":"3113","DOI":"10.1200\/JCO.2005.04.7779","article-title":"Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib","volume":"24","author":"Richardson","year":"2006","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.jgo.2012.02.001_bb0295","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/S1470-2045(11)70081-X","article-title":"Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study","volume":"12","author":"Moreau","year":"2011","journal-title":"Lancet Oncol"},{"issue":"8","key":"10.1016\/j.jgo.2012.02.001_bb0300","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1007\/s00277-010-0925-1","article-title":"Consensus guidelines for the optimal management of adverse events in newly diagnosed, transplant-ineligible patients receiving melphalan and prednisone in combination with thalidomide (MPT) for the treatment of multiple myeloma","volume":"89","author":"Palumbo","year":"2010","journal-title":"Ann Hematol"},{"issue":"8","key":"10.1016\/j.jgo.2012.02.001_bb0305","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1200\/JCO.2010.31.6844","article-title":"Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trial","volume":"29","author":"Palumbo","year":"2011","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.jgo.2012.02.001_bb0310","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.clml.2011.03.006","article-title":"Low venous thromboembolic risk with bortezomib in multiple myeloma and potential protective effect with thalidomide\/lenalidomide-based therapy: review of data from phase 3 trials and studies of novel combination regimens","volume":"11","author":"Zangari","year":"2011","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"29","key":"10.1016\/j.jgo.2012.02.001_bb0315","doi-asserted-by":"crossref","first-page":"4784","DOI":"10.1200\/JCO.2007.14.9641","article-title":"Analysis of herpes zoster events among bortezomib-treated patients in the phase III APEX study","volume":"26","author":"Chanan-Khan","year":"2008","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.jgo.2012.02.001_bb0320","doi-asserted-by":"crossref","first-page":"237","DOI":"10.3816\/CLM.2008.n.031","article-title":"Bortezomib and the increased incidence of herpes zoster in patients with multiple myeloma","volume":"8","author":"Kim","year":"2008","journal-title":"Clin Lymphoma Myeloma"},{"issue":"11","key":"10.1016\/j.jgo.2012.02.001_bb0325","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1001\/archinte.1997.00440320117011","article-title":"Risk factors for postherpetic neuralgia","volume":"157","author":"Choo","year":"1997","journal-title":"Arch Intern Med"},{"issue":"1","key":"10.1016\/j.jgo.2012.02.001_bb0330","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1002\/cncr.24006","article-title":"Acyclovir to prevent reactivation of varicella zoster virus (herpes zoster) in multiple myeloma patients receiving bortezomib therapy","volume":"115","author":"Vickrey","year":"2009","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.jgo.2012.02.001_bb0335","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1200\/JCO.20.2.494","article-title":"Comprehensive geriatric assessment adds information to Eastern Cooperative Oncology Group performance status in elderly cancer patients: an Italian Group for Geriatric Oncology Study","volume":"20","author":"Repetto","year":"2002","journal-title":"J Clin Oncol"},{"issue":"25","key":"10.1016\/j.jgo.2012.02.001_bb0340","doi-asserted-by":"crossref","first-page":"3457","DOI":"10.1200\/JCO.2011.34.7625","article-title":"Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study","volume":"29","author":"Hurria","year":"2011","journal-title":"J Clin Oncol"},{"issue":"13","key":"10.1016\/j.jgo.2012.02.001_bb0345","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1182\/blood-2009-10-163329","article-title":"How I treat elderly patients with myeloma","volume":"116","author":"Mehta","year":"2010","journal-title":"Blood"}],"container-title":["Journal of Geriatric Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879406812000082?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879406812000082?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,11,25]],"date-time":"2018-11-25T13:56:44Z","timestamp":1543154204000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1879406812000082"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,7]]},"references-count":68,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012,7]]}},"alternative-id":["S1879406812000082"],"URL":"https:\/\/doi.org\/10.1016\/j.jgo.2012.02.001","relation":{},"ISSN":["1879-4068"],"issn-type":[{"value":"1879-4068","type":"print"}],"subject":[],"published":{"date-parts":[[2012,7]]}}}